newsfilter
← Latest News
GlobeNewswire·

U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation

CRMD
  • The U.S. Court of Appeals for the Federal Circuit affirmed a judgment that CorMedix Therapeutics' patents covering MINOCIN® for Injection are valid & infringed by Nexus Pharmaceuticals, Inc.
  • The district court previously ruled in favor of CorMedix's subsidiary Melinta Therapeutics on all patent infringement & validity issues following a 2023 bench trial.
  • The Federal Circuit upheld findings that Nexus' generic minocycline product infringes the MINOCIN® patents & rejected Nexus' invalidity challenge.
  • The court affirmed a permanent injunction barring Nexus from marketing its generic product prior to patent expiration.
  • The patents-at-issue are FDA Orange Book listed & protect CorMedix's innovative reformulation of intravenous minocycline used for serious & drug-resistant infections.
  • CorMedix Chairman & CEO Joseph Todisco stated the ruling validates the strength of the company's intellectual property portfolio & reinforces the importance of protecting pharmaceutical innovation.